Follow-up studie: Metformin therapie bij kinderen en adolescenten met neurogene of neuromusculaire aandoeninge

Phase 1

• Conditions: euromuscular and neurological diseases, associated with obesity and insulin resistance; MedDRA version: 9.1Level: LLTClassification code 10022489Term: Insulin resistance; MedDRA version: 9.1Level: PTClassification code 10022489Term: Insulin resistance; MedDRA version: 9.1Level: LLTClassification code 10029883Term: Obesity; MedDRA version: 9.1Level: PTClassification code 10065941Term: Central obesity

• Registration Number: EUCTR2009-009278-29-BE
• Lead Sponsor: Z Leuven

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-01-29
• Study Completion: 2009-08-27
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Adolescents with neurological or neuromuscular diseases
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

type 1 diabetes
Liver failure
Kidney failure

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified